← Human Trials & Peer-Reviewed Studies
Effect of Teriparatide Treatment on Circulating Periostin and Its Relationship to Regulators of Bone Formation and BMD in Postmenopausal Women With Osteoporosis
Plain-language guide to PMID 29365099 (2018): open-label clinical trial study of Teriparatide, osteoporosis and bone density.
Key Facts
- PMID
- 29365099
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2018
- Study type
- Clinical Trial
- Authors
- Gossiel F et al. (8 authors)
- DOI
- 10.1210/jc.2017-00283
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Teriparatide in the context of osteoporosis and bone density, published as a clinical trial.
To determine the effect of teriparatide treatment on circulating levels of periostin and other regulators of bone formation and investigate how changes in periostin relate to changes in bone turnover markers, regulators of bone formation, and bone mineral density (BMD).
Why It Was Studied
A possible modulator of action is periostin.
The effect of teriparatide on periostin is not currently known.
Who Took Part
PubMed indexes the participants as middle-aged adults and older adults, women only.
Twenty women with osteoporosis; a 2-year open-label single-arm study.
How the Study Was Run
In design terms this was a open-label study.
Being open-label, the Teriparatide study did not mask who received what.
Periostin, sclerostin, and Dickkopf-related protein 1, procollagen type I N-terminal propeptide (PINP), and C-telopeptide of type I collagen were measured in fasting serum collected at baseline (two visits) and then at weeks 1, 2, 4, 12, 26, 52, 78, and 104.
BMD was measured at the lumbar spine, total hip, and femoral neck using dual energy x-ray absorptiometry.
What Was Measured
Topics PubMed links to this paper include Absorptiometry, Photon, Adaptor Proteins, Signal Transducing, Biomarkers, Bone Density, Bone Density Conservation Agents, Bone Morphogenetic Proteins and Cell Adhesion Molecules.
What This Means in Plain Language
The paper is an open-label study of Teriparatide in people with osteoporosis and bone density.
Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2018 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Teriparatide compound page, Osteoporosis and bone density research.
Our Notes on the Compound
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.